Found: 9
Select item for more details and to access through your institution.
Front & Back Matter.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 1, doi. 10.1159/000522097
- Publication type:
- Article
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 75, doi. 10.1159/000520278
- By:
- Publication type:
- Article
Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 61, doi. 10.1159/000520277
- By:
- Publication type:
- Article
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 48, doi. 10.1159/000519868
- By:
- Publication type:
- Article
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 38, doi. 10.1159/000519867
- By:
- Publication type:
- Article
APPLE News.
- Published in:
- 2022
- Publication type:
- Proceeding
Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 22, doi. 10.1159/000518940
- By:
- Publication type:
- Article
Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 9, doi. 10.1159/000518619
- By:
- Publication type:
- Article